Peramivir (BCX-1812, RWJ-270201): Potential new therapy for influenza

Expert Opinion on Investigational Drugs

Volumn 11, Issue 6, 2002, Pages 859-869

  Sidwell, Robert W ^a   Smee, Donald F ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

Antiviral; BCX 1812; Influenza virus; Neuraminidase inhibitor; RWJ 270201

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; CYCLOPHOSPHAMIDE; DNA; NEURAMINIC ACID DERIVATIVE; OSELTAMIVIR; OXYGEN; PERAMIVIR; RIMANTADINE; SIALIC ACID DERIVATIVE; SIALIDASE INHIBITOR; VIRUS SIALIDASE; ZANAMIVIR; GUANIDINE DERIVATIVE; SIALIDASE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; IMMUNE DEFICIENCY; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MOUSE; NONHUMAN; RAT; SIDE EFFECT; TOXICITY TESTING; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS VIRULENCE; WILD TYPE; ANIMAL; ANTIBIOTIC RESISTANCE; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; IMMUNOLOGY; ORTHOMYXOVIRUS; REVIEW; SYNTHESIS;

ANIMAL; ANTIVIRAL AGENTS; CLINICAL TRIALS; CYCLOPENTANES; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; HUMAN; INFLUENZA; NEURAMINIDASE; ORTHOMYXOVIRIDAE; ANIMALS; GUANIDINES; HUMANS; INFLUENZA, HUMAN;

EID: 0036016097     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.6.859     Document Type: Article

References (35)

1. Adsorption of influenza hemagglutinins and virus by red blood cells
2. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dihydro-N-trifluoroacetylneuraminic acid (FANA): Mechanism of action
3. Oseltamivir: A clinical and pharmacological perspective
4. Neuraminidase inhibitors for the treatment and prevention of influenza
5. Rational design of potent sialidase-based inhibitors of influenza virus replication
6. BCX-1812 (RWJ-270201): Discovery of a highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design
7. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetyl-neuraminic acid
8. Uptake, metabolism and excretion of orally administered doubled-labeled N-glycoloyl-neuraminic acid and single-labeled 2-deoxy-2,3-dehydro-N-acetylneuraminic acid in mouse and rat
9. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminidate) substrate
10. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir
11. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities
12. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants
13. Influenza type A virus neuraminidase does not play a role in viral entry, replication assembly, or budding
14. Alterations of the stalk of the influenza virus neuraminidase: Deletions and insertions
15. In vivo influenza-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201
16. Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection
17. Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201
18. A pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing
19. Penetration of the neuraminidase inhibitors RWJ-270201, GS-4071, and GS4104 into rat bronchoalveolar linig fluid following IV administration
20. RWJ-270201 (BCX-1812): A novel neuraminidase inhibitor for influenza
21. RWJ-270201 rapidly clears both influenza A and B in challenge studies
22. The immunology of influenza
23. Cellular mechanisms involved in protection and recovery from influenza virus infection in immunodeficient mice
24. Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice
25. Influenza A in immunocompromised patients
26. Antigenic and genetic variation in influenza A (H1N1) virus isolates recovered from a persistently infected immunodeficient child
27. Viral pneumonia in the immunocompromised adult with neoplastic diseases: The role of common community respiratory viruses
28. Resistance to antiviral drugs
29. Progressive murine cytomegalovirus disease after termination of ganciclovir therapy in mice immunosuppressed by cyclophosphamide treatment
30. Immunopotentiation by cyclophosphamide and other cytotoxic agents
31. The influenza virus neuraminidase inhibitor RWJ-270201: Immunological effects and inhibition of influenzal disease in the immunocompromised host
32. Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201
33. Resistance of influenza viruses to neuraminidase inhibitors - A review
34. Safety and efficacy of an oral neuraminidase inhibitor RWJ-270201 in treating experimental influenza A and B in healthy adult volunteers
35. Johnson & Johnson drops influenza drug R & D link with BioCryst